Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03987711 | Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis | PHASE2 | COMPLETED | 151 | — | — | Dec 10, 2019 | Dec 31, 2022 | Jun 22, 2023 | 28 | Australia, Canada |
| Arm | Type | Description |
|---|---|---|
| Warfarin | EXPERIMENTAL | Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0. |
| Apixaban | ACTIVE_COMPARATOR | Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants). |
| No oral anticoagulation | ACTIVE_COMPARATOR | Individuals in this arm will be exposed to a treatment strategy in which no oral anticoagulation is prescribed. |
| Name | Type | Description |
|---|---|---|
| Warfarin | DRUG | Individuals randomized to this arm will be exposed to dose-adjusted daily warfarin targeting an international normalized ratio (INR) of 2.0-3.0. |
| Apixaban | DRUG | Individuals randomized to this arm will receive apixaban 5 mg twice daily (a reduced dose of 2.5 mg twice daily will be given to selected participants). |
| No oral anticoagulation | OTHER | No oral anticoagulation |
Inclusion Criteria: 1. Age ≥ 18 years. 2. Receiving maintenance hemodialysis or peritoneal dialysis for \> 90 days. 3. History of AF or atrial flutter as defined by: (i) AF or atrial flutter on a 12 lead ECG at enrollment, and not due to a reversible cause, or (ii) AF or atrial flutter document...